Firefinch Software’s Post

Artiva Biotherapeutics is looking to raise up to $135 million from an Initial Public Offering (IPO) to fund clinical trials for its leading allogeneic natural killer (NK) cell therapy. The San Diego-based company revealed these plans in a recent Securities and Exchange Commission filing, with expectations of selling 8.7 million shares priced between $14 and $16 each 💰 💵 The major focus for the proceeds will be on advancing the clinical development of AlloNK, a non-genetically modified, cryopreserved NK cell therapy. Currently, AlloNK is being tested in a phase 1 trial for lupus nephritis alongside Roche's Rituxan or Gazyva. It's also part of another study that spans multiple autoimmune indications. By the first half of 2025, we should see some promising data readouts 📉 #Biotechnology #ArtivaBiotherapeutics #ClinicalTrials #NKCellTherapy #IPO #LifeScience #ElixirAssociates #StaffingPartner

Stay up to date on all things #IO and register for tomorrow's #SITC Targets for Cancer IO: A Deep Dive into Clinical Consideration for CD3-Bispecifics and Costimulatory T cell Engagers in Solid #Tumors Webinar! Moderators: Jeremy Myers, PhD - EvolveImmune Therapeutics & Dimitris Skokos, PhD - Regeneron Pharmaceuticals, Inc. Faculty: John Desarjais, PhD - Xencor, Christian Klein, PhD - Roche Innovation Center Zurich & Elizabeth Pham, PhD - Amgen Inc. This webinar will address current studies to develop more effective, safer CD3-targeting bispecific T #cell engagers that maintain clinical efficacy within the immunosuppressive #TME while minimizing cytokine release and other on-target, off-tumor toxicities. Save your spot for tomorrow's webinar: go.sitcancer.org/3YtTUNh

Our portfolio company HAYA Therapeutics has been recognized by Labiotech.eu as one of the top 18 biotech startups in Switzerland, spotlighting its innovative approach to targeting non-coding RNAs to combat fibrotic diseases and age-related conditions: https://lnkd.in/gnPbAhQ As reported by The Financial Times, a groundbreaking anti-aging therapy that mimics regenerative processes seen in axolotl salamanders has shown promise in extending the lifespan of mice by 25%. Read more about the treatment that targets the pro-inflammatory protein IL-11: https://lnkd.in/guvdqyFH New hires at our portfolio companies: HAYA Therapeutics welcomes Eric Adam as their new COO, bringing his extensive experience from the pharmaceutical and diagnostics industries to support their growth and scientific exploration. Meanwhile, Auron Therapeutics, Inc. introduces Serge Messerlian to their board, enhancing their leadership as they advance their innovative cancer therapeutics platform. #ICYDK #ApolloVC #Lifespan #Healthspan #Longevity #VentureCapital

Interesting perspective on future immunotherapeutics

Heading to ISCT 2024? Our agenda is jam-packed with opportunities to explore and move forward with your advanced therapeutics — from exciting speakers to thought-provoking sessions, and educational posters you won't want to miss: 👉 End-to-end manufacturing of autologous CAR T cell therapies with a new cell therapy manufacturing platform 👉 Regulatory T cell expansion in the Xuri cell expansion system W25 👉 Closed, semi-automated harvest of iPSC scale-up workflow using the Sepax C-Pro with CultureWash protocol 👉 Optimization of multiplex CRISPR-Cas9 editing of human primary T cells using lipid nanoparticles (LNPs) and subsequent off-target evaluation 👉 Strategies for producing clinical and commercial RNA-LNP drug products And there's more...follow this link to discover all the ways you can connect with us at ISCT: https://lnkd.in/gsseh3Pu

I am sure many of you are thinking: "Ugh, not more ADCs, that's so passe." But not so fast, folks! There is so much more that a conjugated biologic, antibody or antibody-like molecule (or peptide, small molecule, etc.) could do, from novel payloads like degraders to immunotherapies, to hitting novel targets such as internal proteins, to delivering antigens to APCs. So please join me and my colleague, Viraj Parekh along with our esteemed panelists Greg Dwyer, Asthika Goonewardene, John Lambert, Michael G King Jr, Jeremy Sauer and Michael Stumpp as we take ADCs "To the Next Level." #cancer #oncology #ADCs #antibodies #biotech #pharma

Merus announced interim clinical data as of a data cutoff of March 6, 2024, from the ongoing Phase 1/2 trial of the bispecific antibody Petosemtamab in combination with Pembrolizumab. During the discovery process of Petosemtamab, Merus successfully utilized the tumor organoid platform from our portfolio company Crown Bioscience for target validation, antibody screening, and mechanistic studies. This breakthrough organoid research has significantly shortened the time from initial discovery to clinical trials to just five years. Moreover, Petosemtamab demonstrated more sensitive efficacy in organoids compared to traditional cell lines and PDX animal models, validating the advantages of 3D in vitro tumor organoid models in drug discovery. #MedicalInnovation #CancerResearch #ClinicalTrials #BispecificAntibody #OrganoidTechnology #QimingHealthcare #QimingPortfolio

Heading to ISCT 2024? Our agenda is jam-packed with opportunities to explore and move forward with your advanced therapeutics — from exciting speakers to thought-provoking sessions, and educational posters you won't want to miss: 👉 End-to-end manufacturing of autologous CAR T cell therapies with a new cell therapy manufacturing platform 👉 Regulatory T cell expansion in the Xuri cell expansion system W25 👉 Closed, semi-automated harvest of iPSC scale-up workflow using the Sepax C-Pro with CultureWash protocol 👉 Optimization of multiplex CRISPR-Cas9 editing of human primary T cells using lipid nanoparticles (LNPs) and subsequent off-target evaluation 👉 Strategies for producing clinical and commercial RNA-LNP drug products And there's more...follow this link to discover all the ways you can connect with us at ISCT: https://lnkd.in/es9mr3m7

🖼️ [POSTER] Promega's automated workflow for exosomal RNA isolation enables rapid, high-throughput miRNA extraction for RNA-seq and RT-qPCR, reducing processing time to under 2 minutes. ⬇️ Download the full poster to explore its potential for advancing exosome-based therapeutics: https://bit.ly/4efQYc7

Heading to ISCT 2024? Our agenda is jam-packed with opportunities to explore and move forward with your advanced therapeutics — from exciting speakers to thought-provoking sessions, and educational posters you won't want to miss: 👉 End-to-end manufacturing of autologous CAR T cell therapies with a new cell therapy manufacturing platform 👉 Regulatory T cell expansion in the Xuri cell expansion system W25 👉 Closed, semi-automated harvest of iPSC scale-up workflow using the Sepax C-Pro with CultureWash protocol 👉 Optimization of multiplex CRISPR-Cas9 editing of human primary T cells using lipid nanoparticles (LNPs) and subsequent off-target evaluation 👉 Strategies for producing clinical and commercial RNA-LNP drug products And there's more...follow this link to discover all the ways you can connect with us at ISCT: https://lnkd.in/eK8hVC_4